Article Figures & Data
Figures
- Figure 1.
124I PET/CT calibration. A, NEMA IEC Body Phantom PET acquisitions with 124I for spheres to background activity concentration ratios equal to infinite, 9, 5, and 3, conducted to obtain the recovery coefficients (RC; see Materials and Methods) for dosimetric calculations. B, course of the recovery coefficients as a function of sphere volume represented for different S:B concentration ratios.
- Figure 2.
Bone red marrow dosimetry. A, time course of FIA/mL 131I in the blood of patients during the diagnostic (solid lines) and posttherapy phase (dashed lines). B, time course of FIA (131I) in the body of patients during the diagnostic and posttherapy phase. 124I diagnostic data are rescaled to 131I half time. Different colors refer to different patients.
- Figure 3.
Examples of imaging data in patients. A, 124I-L19SIP PET image 24 hours p.i., showing a hepatic lesion with high antibody uptake. The corresponding transaxial, sagittal, and coronal projections PET/CT fusion images are depicted in B. C, FDG PET image of a lesion in the cerebellar region, visible despite the high metabolic uptake of glucose in the brain (transaxial, sagittal, and coronal projections); the corresponding PET images stemming from the diagnostic phase with 124I-L19SIP (24 hours p.i.) and SPECT images posttherapy from the use of 131I-L19SIP (24 hours p.i.) are depicted in D and E, respectively.
- Figure 4.
Lesions and healthy organs dosimetry. A, time course of FIA/g of tissue in selected brain lesions (dotted lines) and extracranial metastases (continuous lines) of all 6 patients. *, values for extracranial (liver) and brain lesions measured in the same patient. B, FIA/g of tissue time course in various organs from one patient. The 124I diagnostic values have been rescaled to match the physical half-life of 131I (8 days). The profiles thus represent an underestimate of the antibody residence on the lesion, as they contain an exponential component for the decay of the radionuclide.
Tables
- Table 1.
Estimated doses to healthy organs, brain lesions, and extracranial metastases
Organ/lesion Dmean, Gy/GBq Range, Gy/GBq Adrenals 0.192 0.153–0.229 Brain 0.076 0.064–0.086 Breasts 0.142 0.113–0.173 Gall bladder wall 0.194 0.158–0.232 Lower large intestine wall 0.178 0.144–0.221 Small intestine 0.178 0.149–0.213 Stomach wall 0.178 0.143–0.218 Upper large intestine wall 0.182 0.147–0.225 Heart wall 0.205 0.107–0.318 Kidneys 0.553 0.397–0.791 Liver 0.297 0.229–0.346 Lungs 0.340 0.224–0.293 Muscle 0.157 0.127–0.193 Ovaries 0.204 0.188–0.224 Pancreas 0.195 0.156–0.235 Bone red marrow 0.201 0.168–0.256 Osteogenic cells 0.326 0.257–0.411 Skin 0.132 0.106–0.163 Spleen 0.297 0.172–0.413 Testes 0.133 0.124–0.143 Thymus 0.169 0.133–0.204 Thyroid 2.648 0.807–5.650 Urinary bladder wall 0.168 0.142–0.201 Uterus 0.202 0.187–0.222 Total body 0.171 0.138–0.206 Effective dose 0.315 0.220–0.481 Brain lesions 0.376 0.099–1.370 Extracranial lesions 1.408 0.153–5.380 NOTE: The dose of radioactivity to the various organs (normalized per GBq of administered 131I-labeled antibody) was calculated as described in the Materials and Methods. Please note the large range of values in the brain and extracranial lesions, which are in stark contrast with the extremely narrow range observed for the normal organs. The high variability observed for the thyroid reflects a poor compliance of patients for their premedication with Lugol solution during the diagnostic phase of the study.
- Table 2.
Estimated doses to individual lesions
Mass Avg. dose Avg. dose Patient Lesion g Gy/GBq Gy 1 Brain, left frontal 22.8 0.20 1.48 Brain, right occipital 23.1 0.24 1.75 Lung, right upper lobe 0.8 0.15 1.11 2 Brain, cerebellar vermis 13.7 0.66 4.41 Brain, left lower temporomedial 0.4 0.43 2.83 Liver 27.0 5.38 35.84 3 Brain, right anterior frontal 7.0 0.22 1.61 Brain, left central frontal 3.5 0.10 0.73 Brain, right nuclear 2.5 0.21 1.55 Skull, left occipital theca 4.0 0.98 7.24 Pelvis 8.0 1.46 10.77 Lung 34.1 0.18 1.34 4 Brain, left cerebellar 2.5 1.37 8.15 Liver 40.9 1.01 5.98 5 Brain, posterior frontal 1.8 0.45 2.65 6 Brain, left frontal operculum 5.8 0.21 1.25 Brain, left posterior frontal 3.2 0.19 1.12 Brain, right frontal coronal 2.5 0.23 1.38 Vertebra 10.0 0.69 4.11
Supplementary Data
Files in this Data Supplement:
- Supplementary Table 1 - PDF file - 70K, 124I-dosimetry data to healthy organs.
Volume 1, Issue 2
